BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NBTXR3 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NBTXR3\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04484909-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:NBTXR3: Phase 1 readout est. (NCT04484909)
DESCRIPTION:NBTXR3\, phase 1.\nStudy: NBTXR3 Activated by Radiation Therapy
  for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic
  Cancer\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04484909
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03589339-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:NBTXR3: Phase 1 readout est. (NCT03589339)
DESCRIPTION:NBTXR3\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: NBTXR3 A
 ctivated by Radiotherapy for Patients With Advanced Cancers Treated With A
 n Anti-PD-1 Therapy\nEstimated primary completion: 30 April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03589339
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04615013-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:NBTXR3: Phase 1 readout est. (NCT04615013)
DESCRIPTION:NBTXR3\, phase 1.\nStudy: NBTXR3\, Chemotherapy\, and Radiation
  Therapy for the Treatment of Esophageal Cancer\nEstimated primary complet
 ion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nbtxr3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04615013
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039632-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:NBTXR3: Phase 1/2 readout est. (NCT05039632)
DESCRIPTION:NBTXR3\, phase 1/2.\nStudy: Phase I/II Randomized Study of NBTX
 R3 Activated by Abscopal or RadScopal Radiation in Combination With Immuno
 therapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies\nEst
 imated primary completion: 1 February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05039632
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04505267-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:NBTXR3: Phase 1 readout est. (NCT04505267)
DESCRIPTION:NBTXR3\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: NBTXR3 a
 nd Radiation Therapy for the Treatment of Inoperable Recurrent Non-small C
 ell Lung Cancer\nEstimated primary completion: 31 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04505267
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892173-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:NBTXR3: Phase 3 readout est. (NCT04892173)
DESCRIPTION:NBTXR3\, phase 3.\nStudy: JNJ-90301900 (NBTXR3) Activated by Ra
 diotherapy With or Without Cetuximab in LA-HNSCC\nEstimated primary comple
 tion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 btxr3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04892173
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219212-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:NBTXR3: Phase 1 readout est. (NCT07219212)
DESCRIPTION:NBTXR3\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nStud
 y: A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in P
 articipants With Locally Advanced Head and Neck Squamous Cell Carcinoma\nE
 stimated primary completion: 14 July 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07219212
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224152-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:NBTXR3: Phase 1/2 readout est. (NCT07224152)
DESCRIPTION:NBTXR3\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: NBTXR3
  With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Can
 cer\nEstimated primary completion: 30 August 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07224152
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667908-2634@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:NBTXR3: Phase 2 readout est. (NCT06667908)
DESCRIPTION:NBTXR3\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidati
 on Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nbtxr3#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06667908
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
